Caplyta (lumateperone) is not classified as a mood stabilizer. It is formally classified as an atypical antipsychotic. However, it is FDA-approved to treat depressive episodes in bipolar I and bipolar II disorder, which is one of the roles traditionally filled by mood stabilizers. This overlap is why the question comes up so often, and the answer depends partly on how strictly you define “mood stabilizer.”
What Caplyta Is Approved to Treat
The FDA has approved Caplyta for three conditions in adults: schizophrenia, depressive episodes associated with bipolar I or II disorder (bipolar depression), and major depressive disorder when added to an antidepressant. For bipolar depression specifically, it can be used on its own or alongside lithium or valproate.
That bipolar depression approval is significant. Caplyta is one of a small number of medications cleared to treat bipolar II depression as a standalone treatment, not just as an add-on to another drug. Its effectiveness was established in a six-week clinical trial in adults meeting diagnostic criteria for depressive episodes in both bipolar I and bipolar II disorder. A meta-analysis published in the International Journal of Neuropsychopharmacology found that patients taking Caplyta had 27% higher response rates for bipolar depression compared to placebo.
Why It Doesn’t Qualify as a Mood Stabilizer
The term “mood stabilizer” has a specific meaning in psychiatry, even though no regulatory body officially defines the category. A widely cited framework published in BJPsych Open lays out the criteria: a true mood stabilizer must treat manic symptoms (not just depression), prevent future mood episodes over the long term, and not make either pole of bipolar disorder worse.
Caplyta falls short on at least two of those counts right now. It has no FDA approval for treating mania, and it has no established track record for long-term relapse prevention. A phase 3 clinical trial is currently underway testing whether Caplyta can treat acute manic episodes in bipolar I disorder, but results are not yet available. Until that data exists, Caplyta addresses only the depressive side of bipolar disorder, which disqualifies it from the mood stabilizer label under most clinical definitions.
Traditional mood stabilizers like lithium and valproate treat both mania and depression and have decades of evidence supporting their ability to prevent future episodes. Caplyta doesn’t have that breadth of evidence yet.
How Caplyta Works Differently
Caplyta has an unusual mechanism compared to other antipsychotics, which is part of why it gets lumped in with mood stabilizers in casual conversation. It acts on three brain signaling systems simultaneously: dopamine, serotonin, and glutamate.
Most antipsychotics work primarily by blocking dopamine receptors. Caplyta does this too, but with a twist. It partially activates dopamine receptors on the sending side of the nerve connection while blocking them on the receiving side. This dual action means it needs to occupy only about 40% of dopamine receptors to be effective, far less than most antipsychotics require. That lower occupancy is thought to be the reason Caplyta causes fewer movement-related side effects than many drugs in its class.
Caplyta also blocks serotonin receptors with an affinity roughly 60 times greater than its dopamine-blocking strength, and it inhibits the recycling of serotonin in a way that resembles how some antidepressants work. On top of that, it is the first antipsychotic shown to boost the activity of glutamate receptors in the prefrontal cortex, the brain region involved in planning, decision-making, and emotional regulation. This triple action across multiple brain pathways likely explains its effectiveness in bipolar depression, even though it doesn’t fit neatly into the mood stabilizer box.
Side Effects Compared to Mood Stabilizers
One reason people ask whether Caplyta could replace a mood stabilizer is side effects. Traditional mood stabilizers come with well-known downsides: lithium requires regular blood monitoring and can affect the kidneys and thyroid over time, while valproate carries risks of weight gain, liver problems, and serious birth defects. Many patients find these side effects difficult to tolerate long-term.
Caplyta’s side effect profile is generally considered lighter than older atypical antipsychotics, particularly when it comes to weight gain and metabolic changes. That said, the FDA label still warns about the potential for elevated blood sugar, cholesterol changes, and weight gain, as these risks apply to the atypical antipsychotic class as a whole. Monitoring of weight, blood sugar, and lipids is recommended when starting and continuing the medication.
The most commonly reported side effects in clinical trials were drowsiness, dizziness, nausea, and dry mouth. For many patients, these are milder than what they experience on traditional mood stabilizers or older antipsychotics, which partly explains the interest in using Caplyta as an alternative.
What This Means for Bipolar Treatment
If you’re taking Caplyta for bipolar depression, it’s filling one role that a mood stabilizer would, but not all of them. It can help lift you out of a depressive episode, and it can be taken alone or alongside a traditional mood stabilizer. What it hasn’t been proven to do is prevent your next manic episode or keep your mood stable over months and years the way lithium or valproate can.
For people with bipolar II disorder, where full-blown mania doesn’t occur, this distinction may matter less in practice. Bipolar II involves hypomanic episodes (less severe than mania) and more time spent in depression, so a medication that effectively treats the depressive side carries significant value. For bipolar I, where manic episodes can be severe and dangerous, relying on Caplyta alone without a proven anti-manic agent would leave a gap in coverage.
The ongoing phase 3 trial testing Caplyta for acute mania could eventually change its classification. If the drug proves effective against both poles of bipolar disorder and demonstrates long-term relapse prevention, it would meet the clinical criteria for a mood stabilizer. For now, it is an atypical antipsychotic with strong evidence for bipolar depression and a mechanism of action that sets it apart from others in its class.